Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

التفاصيل البيبلوغرافية
العنوان:	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
المؤلفون:	Robinson, Jennifer G., Farnier, Michel, Kastelein, John J.P., Roth, Eli M., Taskinen, Marja-Riitta, Colhoun, Helen M., Brunet, Aurelie, DiCioccio, A. Thomas, Lecorps, Guillaume, Pordy, Robert, Baccara-Dinet, Marie T., Cannon, Christopher P.
المصدر:	In Journal of Clinical Lipidology November-December 2019 13(6):979-988
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	19332874
DOI:	10.1016/j.jacl.2019.10.004